Subscribe
Be the first with the news that moves the market- Revive Therapeutics (CSE:RVV) is expanding the scope of a sponsored research partnership agreement with the University of Wisconsin-Madison
- The partnership will evaluate new psilocybin formulations and include a Phase 1 clinical study to investigate the therapeutic applications of psilocybin
- Research currently under way at the University is focused on tannin-chitosan composites in the form of thin films, hydrogels and 3D foams
- Final formulations of the products will be assessed in pre-clinical and clinical studies relating to various diseases and disorders
- Revive Therapeutics (RVV) is down 2.22 per cent and is trading at C$0.22 per share
Revive Therapeutics (CSE:RVV) is expanding the scope of a sponsored research partnership agreement with the University of Wisconsin-Madison.
Current research being carried out at the University of Wisconsin-Madison is focused on tannin-chitosan composites in the form of thin films, hydrogels and 3D foams. Revive noted that the tannin-chitosan composite thin films are the most promising candidate to deliver therapeutic doses of psilocybin into the oral cavity.
The research will include the development of various composite formulations, physio-chemical characterisation of the composite materials, and the rate of psilocybin release from these composites.
The final formulations of these products will be assessed in pre-clinical and clinical studies relating to a number of diseases and disorders.
Michael Frank, CEO of Revive Therapeutics, said that expanded partnership will serve as a platform to create unique psychedelic-based therapeutics for clinical research targeting specific medical needs, such as addiction use disorders.
He also noted that the work will help to create a robust product pipeline with the aim to pursue the FDA regulatory pathway for commercialisation.
In addition, Revive plans to finalise a sponsorship program regarding a Phase 1 clinical study, which will focus on assessing psilocybin as a potential treatment for an as-yet undisclosed addiction disorder.
The study will be undertaken at the University of Wisconsin-Madison’s School of Medicine and Public Health. It will also involve the School of Pharmacy, which holds a Wisconsin special authorisation and DEA-issued license to carry out clinical research with psilocybin.
Revive Therapeutics (RVV) is down 2.22 per cent and is trading at C$0.22 per share at 3:39pm EDT.
